MENU
Aim higher

MimoVac-E

Novel therapeutic mimotope-AAVLP cancer vaccine engineered using NGS-guided molecular evolution

We will develop a vaccine that mobilizes the patient’s immune system for a potent and long-lasting response against cancer cells in head and neck cancer (HNC), where there is a major unmet medical need. Based on a clinically approved monoclonal antibody, we will develop novel cancer mimotopes displayed numerously on adeno-associated virus-like particles (AAVLP). The vaccine is validated in vitro and preclinically during the project, and successively continued into a clinical phase I study.
Acronym: 
MimoVac-E
Project ID: 
12 406
Ranking: 
9
Cut-off: 
9
Start date: 
01-09-2018
Project Duration: 
36months
Project costs: 
1 188 900.00€
Technological Area: 
Virus, Virology, Vaccines/ Antiobiotics / Bacteriology
Market Area: 
Pharmaceuticals/fine chemicals